Blueprint Medicines (BPMC) PT Lowered to $100 at Wedbush, After Trial Misses Endpoints

April 28, 2020 2:31 PM EDT
Get Alerts BPMC Hot Sheet
Price: $106.61 -2.61%

Rating Summary:
    13 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten lowered the price target on Blueprint Medicines (NASDAQ: BPMC) to $100.00 (from $122.00) while maintaining a Outperform rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change